In today’s briefing:
- FnGuide Top10 Equal Weight Index Rebalance Preview: Celltrion Could Replace Samsung SDI
- Bangkok Dusit Medical Services (BDMS TB): Core Business Drives 4Q23 Result; Outlook Remains Positive
- Biogen Inc: The Breakthrough Drug Portfolio Set to Dominate Neurology – See How They’re Changing the Game! – Major Drivers
- Zoetis Inc: Librela & Other Factors Contributing To Its Competitive Edge! – Financial Forecasts
FnGuide Top10 Equal Weight Index Rebalance Preview: Celltrion Could Replace Samsung SDI
- The Samsung KODEX Fn Top10 Equal Weight ETF (395170 KS) tracks the FnGuide Top 10 Equal Weight Index and has an AUM of US$241m.
- We expect Celltrion Inc (068270 KS) will replace Samsung SDI (006400 KS) in the index at the March rebalance.
- There will be 0.26x ADV to buy in Celltrion Inc (068270 KS) while passives will need to sell 0.17x ADV of Samsung SDI (006400 KS).
Bangkok Dusit Medical Services (BDMS TB): Core Business Drives 4Q23 Result; Outlook Remains Positive
- Bangkok Dusit Medical Services (BDMS TB) reported double-digit top and bottomline growth in 4Q23. Growth was attributable to international and Thai non-COVID patient revenues growth.
- In 2023, total revenue was THB102B, up 10% YoY, matching the higher end of the guidance range of 9–10%. EBITDA margin of 24.2% remained higher than guidance of 24.0%.
- In 2024, BDMS expects healthcare business to grow continuously on the back of secular tailwinds in the healthcare sector in Thailand.
Biogen Inc: The Breakthrough Drug Portfolio Set to Dominate Neurology – See How They’re Changing the Game! – Major Drivers
- Biogen concluded its Fourth Quarter and Full Year 2023, announcing several positive strides and addressing potential drawback in its prospects moving forward with its outlook for 2024.
- Biogen emphasized its objective of returning to sustainable growth.
- Chris Viehbacher, Biogen’s President and Chief Executive Officer, reported positive earnings per share guidance, a notable element for consideration.
Zoetis Inc: Librela & Other Factors Contributing To Its Competitive Edge! – Financial Forecasts
- Zoetis, a leading company in animal health, reported strong results for the full year with an operational revenue growth of 7% which was driven by the success of their diverse portfolio, innovation and the commitment of their colleagues.
- Their products designed for pain relief in osteoarthritis contributed towards a 6% growth in the U.S. sector and 9% operational growth internationally.
- The companion animal portfolio showed an operational growth increasing by 8%, while the livestock portfolio also witnessed improvements, growing by 6%.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
